These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20040247)

  • 21. Quantitative transcranial sonography of the substantia nigra as a predictor of therapeutic response to intravenous iron therapy in restless legs syndrome.
    Garcia-Malo C; Wanner V; Miranda C; Romero Peralta S; Agudelo L; Cano-Pumarega I; Granizo JJ; Garcia-Borreguero D
    Sleep Med; 2020 Feb; 66():123-129. PubMed ID: 31875533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcranial sonography in Parkinson's disease.
    Bor-Seng-Shu E; Pedroso JL; Andrade DC; Barsottini OG; Andrade LA; Barbosa ER; Teixeira MJ
    Einstein (Sao Paulo); 2012; 10(2):242-6. PubMed ID: 23052464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative study of the substantia nigra echogenicity and
    Mašková J; Školoudík D; Štofaniková P; Ibarburu V; Kemlink D; Zogala D; Trnka J; Krupička R; Šonka K; Růžička E; Dušek P
    Sleep Med; 2020 Jun; 70():116-123. PubMed ID: 32403038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The measuring of substantia nigra hyperechogenicity in an Italian cohort of Parkinson disease patients: a case/control study (NOBIS Study).
    Prati P; Bignamini A; Coppo L; Naldi A; Comi C; Cantello R; Gusmaroli G; Walter U
    J Neural Transm (Vienna); 2017 Jul; 124(7):869-879. PubMed ID: 28451942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Transcranial sonography of substantia nigra in patients with Parkinson's disease].
    Miwa H
    Rinsho Shinkeigaku; 2013; 53(11):981-2. PubMed ID: 24291852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcranial sonography of the substantia nigra and its correlation with DAT-SPECT in the diagnosis of Parkinson's disease.
    Li DH; Zhang LY; Hu YY; Jiang XF; Zhou HY; Yang Q; Kang WY; Liu J; Chen SD
    Parkinsonism Relat Disord; 2015 Aug; 21(8):923-8. PubMed ID: 26066091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substantia nigra echogenicity is correlated with nigrostriatal impairment in Machado-Joseph disease.
    Pedroso JL; Bor-Seng-Shu E; Felício AC; Braga-Neto P; Hoexter MQ; Teixeira MJ; Bressan RA; Barsottini OG
    Parkinsonism Relat Disord; 2013 Aug; 19(8):742-5. PubMed ID: 23680416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Illicit stimulant use is associated with abnormal substantia nigra morphology in humans.
    Todd G; Noyes C; Flavel SC; Della Vedova CB; Spyropoulos P; Chatterton B; Berg D; White JM
    PLoS One; 2013; 8(2):e56438. PubMed ID: 23418568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative transcranial sonography in Wilson's disease and healthy controls: Cut-off values and functional correlates.
    Tribl GG; Trindade MC; Almeida KJ; Alves RC; de Andrade DC; Fonoff ET; Machado AA; Teixeira MJ; Barbosa ER; Bor-Seng-Shu E
    J Neurol Sci; 2018 Feb; 385():69-74. PubMed ID: 29406916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Left-hemispheric predominance of nigrostriatal deficit in isolated REM sleep behavior disorder.
    Iranzo A; Stefani A; Niñerola-Baizan A; Stokner H; Serradell M; Vilas D; Holzknecht E; Gaig C; Pavia J; Lomeña F; Reyes D; Seppi K; Santamaria J; Högl B; Tolosa E; Poewe W;
    Neurology; 2020 Apr; 94(15):e1605-e1613. PubMed ID: 32161031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy.
    Berg D; Jabs B; Merschdorf U; Beckmann H; Becker G
    Biol Psychiatry; 2001 Sep; 50(6):463-7. PubMed ID: 11566164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Echogenic substantia nigra in patients with orthostatic tremor.
    Spiegel J; Behnke S; Fuss G; Becker G; Dillmann U
    J Neural Transm (Vienna); 2005 Jul; 112(7):915-20. PubMed ID: 15526141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substantia nigra echogenicity in Friedreich's ataxia patients.
    Sierra M; Infante J; Berciano J
    Cerebellum; 2013 Aug; 12(4):437-40. PubMed ID: 23239281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between substantia nigra features detected by sonography and Parkinson disease symptoms.
    Bártová P; Skoloudík D; Ressner P; Langová K; Herzig R; Kanovsky P
    J Ultrasound Med; 2010 Jan; 29(1):37-42. PubMed ID: 20040773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substantia nigra echogenicity in hereditary ataxias with and without nigrostriatal pathology: a pilot study.
    Martínez-Sánchez P; Cazorla-García R; Sanz-Gallego I; Correas-Callero E; Pulido-Valdeolivas I; Arpa J
    Cerebellum; 2015 Jun; 14(3):240-6. PubMed ID: 25592070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sonographic substantia nigra hypoechogenicity in polyneuropathy and restless legs syndrome.
    Godau J; Manz A; Wevers AK; Gaenslen A; Berg D
    Mov Disord; 2009 Jan; 24(1):133-7. PubMed ID: 19170194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substantia nigra echogenicity correlated with clinical features of Parkinson's disease.
    Zhou HY; Sun Q; Tan YY; Hu YY; Zhan WW; Li DH; Wang Y; Xiao Q; Liu J; Chen SD
    Parkinsonism Relat Disord; 2016 Mar; 24():28-33. PubMed ID: 26842545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sonographic abnormality of the substantia nigra in melanoma patients.
    Rumpf JJ; Weise D; Fricke C; Wetzig T; Simon JC; Classen J
    Mov Disord; 2013 Feb; 28(2):219-23. PubMed ID: 23114984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new assessment tool for Parkinson disease: the nigral lesion load obtained by transcranial sonography.
    Sanzaro E; Iemolo F; Duro G; Malferrari G
    J Ultrasound Med; 2014 Sep; 33(9):1635-40. PubMed ID: 25154946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.